Depressed Jane

Boosting an exercise-related gene in the brain works as a powerful anti-depressant in mice-a finding that could lead to a new anti-depressant drug target, according to a Yale School of Medicine report in Nature Medicine. “The VGF exercise-related gene and target for drug development could be even better than chemical antidepressants because it is already present in the brain,” said Ronald Duman, professor of psychiatry and senior author of the study. [click link for full article]

Read full article

Popularity: unranked [?]

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of major depressive disorder (MDD) in adults. “Relapse, the re-emergence of depressive symptoms after a successful treatment of depression, is a significant clinical concern,” says Doug Williamson, M.D., Cymbalta associate medical director for Eli Lilly and Company. [click link for full article]

Read full article

Popularity: unranked [?]

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the maintenance treatment of major depressive disorder (MDD) in adults. “Relapse, the re-emergence of depressive symptoms after a successful treatment of depression, is a significant clinical concern,” says Doug Williamson, M.D., Cymbalta associate medical director for Eli Lilly and Company. [click link for full article]

Read full article

Popularity: unranked [?]

Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) announced that the US Food and Drug Administration (FDA) has granted tentative approval for the Company’s Abbreviated New Drug Application (ANDA) for Escitalopram Oxalate Tablets (escitalopram), 5 mg, 10 mg, and 20 mg. Escitalopram is indicated for the treatment of major depressive disorder. [click link for full article]

Read full article

Popularity: unranked [?]